Trial Profile
A preliminary study evaluating correlation of indicators of inflammation and response in patients (pts) treated with Nivolumab or Docetaxel in Non-small cell lung cancer patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jun 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- 14 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology